ANRO - Latest News
Alto Neuroscience, Inc. (ANRO), operates in Healthcare / Biotechnology, trades on NYSE.
Market capitalization stands near $775.2M. Beta to the broader market is 1.16.
The article list below shows the most recent ANRO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ANRO Headlines
Here's Why You Should Add ANRO Stock to Your Portfolio Now
zacks.com - Oct 14, 2026
Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
gurufocus.com - Sep 9, 2026
Alto Neuroscience, Inc.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
businesswire.com - Sep 9, 2026
MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc.
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $37.25 Average PT from Analysts
defenseworld.net - Aug 31, 2026
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven analysts that are
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
businesswire.com - Aug 27, 2026
MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc.
How News Affects ANRO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ANRO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ANRO news questions
- What is the latest ANRO news headline?
- The most recent ANRO headline (Oct 14, 2026) is "Here's Why You Should Add ANRO Stock to Your Portfolio Now". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ANRO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ANRO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ANRO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.